Reports of deaths potentially linked to the treatment have cast a shadow on what many hail as a landmark approval. The US Food and Drug Administration (FDA) has approved lecanemab, the second-ever treatment for Alzheimer’s disease intended to tackle the root of the condition and slow cognitive decline. Researchers welcome the decision, but the excitement […]
